Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain

July 30, 2025 – Under this collaboration, SD Pharma will enhance Oncopeptides’ commercial reach in regions and hospitals beyond its’ core focus areas.

Read more

Oncopeptides announces acceptance of Spanish and Italian Real-World data at IMS Annual Meeting

July 23, 2025 – Oncopeptides today announces that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20.

Read more

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled

May 20, 2025

Oncopeptides AB today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain.

Read more

New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients

April 16, 2025

Oncopeptides announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Read more

FDA removes clinical hold of Oncopeptides’ pipeline drug OPD5

April 1, 2025

Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5. 

Read more

Investor news

Sofia Heigis interviewed by Redeye

July 14, 2025

Redeye's analyst Richard Ramanius interviews Sofia regarding last week's newsflow. The interview is held in Swedish.

Read more

Oncopeptides announces net sales for Q2 2025

July 9, 2025

Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company´s projections and assumed market expectations.

Read more

Pepaxti included in European Guidelines for the treatment of multiple myeloma

July 8, 2025

Read more

All Company news

All Science news

All Investor news

Press release - July 30, 2025

Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain

Read press release

Latest press releases

All press releases

Upcoming events

2025-07-22 - 2025-08-20

Silent period

Other

2025-08-21

Interim Report Q2 2025

Report

2025-10-06 - 2025-11-04

Silent period

Other

Full calendar
CEO Sofia Heigis - Oncopeptides AB

Released May 15, 2025

Oncopeptides publishes Q1 report 2025

Read report

Download

“Momentum across key markets with 161 % sales growth year over year, Japan partnership negotiations progressing, and future U.S. prospects reignited”

CEO Sofia Heigis

 

See the Webcast

The presenation in PDF

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q2 2025 will be published August 21, 2025

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail